Research Article
Artificial Intelligence Enabled Early Drug Discovery and Pre-Clinical Testing: A Paradigm Shift Towards Automation
@INPROCEEDINGS{10.4108/eai.19-12-2025.2366269, author={Parul Nain and Atin Kalra and Raman Kumar Goyal and Pradip Nirbhavane and Satish Sardana}, title={Artificial Intelligence Enabled Early Drug Discovery and Pre-Clinical Testing: A Paradigm Shift Towards Automation}, proceedings={Proceedings of the 1st International Conference on Computational Techniques in Data Science, IICTDS 2025, 19-20 December 2025, Chandigarh, India}, publisher={EAI}, proceedings_a={IICTDS}, year={2026}, month={11}, keywords={artificial intelligence (AI) early drug discovery drug screening machine learning (ML) preclinical drug development and animal testing}, doi={10.4108/eai.19-12-2025.2366269} }- Parul Nain
Atin Kalra
Raman Kumar Goyal
Pradip Nirbhavane
Satish Sardana
Year: 2026
Artificial Intelligence Enabled Early Drug Discovery and Pre-Clinical Testing: A Paradigm Shift Towards Automation
IICTDS
EAI
DOI: 10.4108/eai.19-12-2025.2366269
Abstract
Artificial intelligence (AI) is rapidly transforming the process of drug discovery and development and supporting all the stages involved in bringing a potential drug to the market. Currently, more than 30 drug molecules developed by using AI are in various stages of drug development. Artificial intelligence usage has an important part in reducing the time and costs associated with bringing new drugs to market. This article highlights the latest AI advancements and patents in the field of drug discovery and the preclinical stage of drug development. However, there are many ethical concerns which are associated with the use of AI in multiple stages of drug development, and they must be addressed.
Copyright © 2025–2026 EAI